Autolus Therapeutics present clinical data updates at the American Society of Haematology (ASH) Annual Meeting 2022

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, has announced the online publication of three posters with updates from three Phase 1 clinical trials to be presented at the American Society of Haematology (ASH) Annual Meeting.

“It’s great to be presenting clinical updates for AUTO1/22 in paediatric B-ALL and AUTO4 in peripheral T cell Lymphoma. AUTO1/22 shows encouraging response rates in patients ineligible for commercial CAR T therapy, with 83% of patients achieving MRD negative complete responses.” – Dr Martin Pule, Chief Scientific Officer at Autolus.

Read the full story from Autolus.